CTLA4 and neoplasm: Combination therapy with anti-PD-L1 and anti-CTLA4 increased effector T cell and F4/80+ macrophage populations in tumor draining lymph nodes of a transgenic murine model, and combination therapy also protected against tumor re-challenge in a syngeneic model (47).